MEDWAVE
PEER REVIEWED MEDICAL JOURNAL

REVIEWS

Available evidence on integrating COVID-19 into sentinel surveillance systems: A scoping review

Jorge Gualotuña-Suntaxi[a], Diana Pérez-Muñoz[a], Raynier Zambrano-Villacres[b], Ana Karina Zambrano[c], Daniel Simancas-Racines[d], Jaime Angamarca-Iguago[d]*

[a]Maestría en Epidemiología con mención en Investigación Clínica Aplicada, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador; [b]Escuela de Nutrición y Dietética, Universidad Espíritu Santo, Samborondón, Ecuador; [c]Centro de Investigación Genética y Genómica, Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador; [d]Centro de Investigación en Salud Pública y Epidemiología Clínica (CISPEC), Facultad de Ciencias de la Salud Eugenio Espejo, Universidad UTE, Quito, Ecuador

ABSTRACT

INTRODUCTION The COVID-19 pandemic exposed the weaknesses of epidemiological surveillance systems and highlighted the need to integrate new respiratory viruses into sentinel surveillance systems. However, current evidence on their effectiveness remains limited.

AIM This project conducts a scoping review to describe the available evidence on the integration of COVID-19 into sentinel surveillance systems.

METHODS The included studies addressed sentinel surveillance in the context of the pandemic following the World Health Organization declaration. A systematic search was performed in databases including MEDLINE, LILACS, EPISTEMONIKOS, and DIMENSIONS, selecting observational studies and systematic reviews. Data collection and analysis were organized into categories such as clinical characteristics, timely detection, geographic representativeness, co-infection, and adaptability with genomic surveillance. Seventeen studies reporting on COVID-19 integration impact and one preliminary WHO report were identified.

RESULTS Results identified the most prevalent symptoms in the general population: fever (73%), cough (51.8%), loss of taste or smell (45.1%), hypoxemia (33%), and sputum production (23.9%). A high correlation was obtained between SARI cases or hospitalizations due to respiratory infection and the incidence of COVID-19 ($\rho = 0.78$ and $\rho = 0.82$ respectively).

CONCLUSIONS Integrating COVID-19 into the sentinel surveillance system could improve detection, response, and follow-up capacity. Additionally, implementing standardized case definitions promotes more efficient use of laboratory resources, thereby enhancing the sustainability of the surveillance system.

KEYWORDS COVID-19, Sentinel surveillance, severe acute respiratory infections, epidemiology, SARI

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first reported in Wuhan, China, in late 2019, triggered the COVID-19 pandemic, which impacted respiratory infection surveillance activities. Currently, many countries are transitioning out of a state of emergency, following the recommendations of agencies such as the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) [1]. Sentinel surveillance is based on information from "sentinel units", which report on a predetermined sample of individuals in whom the event of interest occurs [2]. The WHO recommends specific case definitions, including Acute Respiratory Infection (ARI), Severe Acute Respiratory Infection (SARI), and Influenza-like Illness (ILI) [3]. Additionally, the information is crucial in public health. The data obtained can guide strategies to limit the spread of SARS-CoV-2, as well as to reduce morbidity and mortality. WHO suggests maintaining and strengthening sentinel surveillance [4]. Finally, efforts have been initiated to assess priorities from a country perspective, identifying challenges and gaps in

* **Corresponding author** jaime.angamarca@ute.edu.ec
Citation Gualotuña-Suntaxi J, Pérez-Muñoz D, Zambrano-Villacres R, Zambrano AK, Simancas-Racines D, Angamarca-Iguago J . Available evidence on integrating COVID-19 into sentinel surveillance systems: A scoping review. Medwave 2025;25(09):e3026
DOI 10.5867/medwave.2025.09.3026
Submitted Oct 14, 2024, **Accepted** May 22, 2025,
Published Oct 20, 2025
Postal address Av. Occidental y Mariana de Jesús, Quito, Ecuador

MAIN MESSAGES

- The scoping review focused on examining the available evidence for sentinel surveillance systems, including clinical characteristics, timely detection and response, geographic representativeness, efficient resource utilization, and adaptability in the context of genomic surveillance.
- The integration of COVID-19 into sentinel surveillance systems for severe acute respiratory infections has shown that it could have a favorable impact.
- Despite the observed benefits, the available evidence is limited and heterogeneous due to differences in sentinel surveillance systems in different countries.

integrating COVID-19 into surveillance systems for influenza and other respiratory viruses [5].

In this context, the integration of COVID-19 into sentinel surveillance systems for severe acute respiratory infection represents a key tool for more efficient monitoring against future pandemic threats. This project aims to describe the available evidence on the impact of integration, analyze the responsiveness of epidemiological surveillance systems, monitor virus variants, and evaluate health interventions.

METHODS

This review followed the five stages described in the Arksey and O'Malley framework [6].

Stage 1: identification of the research question

The following question directed this structured review:

What is the available evidence of the impact of COVID-19 integration into sentinel surveillance systems on COVID-19 management?

Phase 2: identification of relevant studies

A systematic search was conducted in the following databases: MEDLINE/PubMed, LILACS, Epistemonikos and Dimensions. The latter incorporates artificial intelligence, which optimizes information retrieval by applying machine learning algorithms and natural language processing. The search strategy used in Dimensions was: ("COVID-19" OR "coronavirus" OR "SARS-CoV-2") AND ("sentinel surveillance" OR "surveillance system" OR "sentinel networks" OR "sentinel surveillance system" OR "sentinel surveillance system" OR "sentinel surveillance system" OR "sentinel surveillance system") AND ("Universal Surveillance" OR "Mass Surveillance").

After selecting the studies, a literature review of the references from the selected articles was conducted. The systematic search was limited to publications in English and Spanish, and focused on studies published since 2019. In addition, a search of gray literature was included in technical and operational reports issued by public health agencies, such as the WHO, and by governmental entities. Incomplete studies, opinion articles, narrative reviews, articles that did not include the impact of COVID-19 integration into sentinel surveillance systems, and studies conducted outside the temporal context of the SARS-CoV-2 pandemic were excluded.

Phase 3: study selection

Two authors (JGS and JAI) independently reviewed titles and abstracts. They then reviewed relevant articles in their entirety. Articles describing the integration of COVID-19 into sentinel surveillance systems and case definition criteria confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) were included. If the two reviewers could not agree on the inclusion of the abstract or the full article, the opinion of a third reviewer (DPM) was sought.

Phase 4: data charting process

Two reviewers (JGS and DPM) developed the standardized matrix in Microsoft Excel ® (Annex 1). Two authors (JGS and JAI) independently performed the data extraction. Information related to general data (title, year of publication, country) and methodological data (research design, objective and clinical outcomes) was collected. The critical appraisal tools of the Joanna Briggs Institute (JBI) [7] were applied to analyze the reliability, relevance, and results of the included articles.

Phase 5: summary of results

The results were organized into the following categories: clinical characteristics, timely detection and response, geographic representativeness, efficient use of resources, coinfection, and adaptability with genomic surveillance. The review was conducted according to the Preferred Reporting Items for a Systematic Review and Meta-Analysis guidelines extension for scoping reviews (PRISMA-SCR) [8].

RESULTS

We identified 44 studies exploring the integration of COVID-19 into sentinel surveillance systems (Figure 1).

The included studies were: 1 systematic review and 16 cross-sectional studies from: United Kingdom [9], Spain [10–12], Belgium [13], Kenya [14], China [15], United States [16–18], Portugal [19], Egypt [20], Israel [21,22], Uganda [23], Niger [24], Bangladesh [25] and a WHO report [26]. The studies reported data between January 30, 2020, and December 15, 2023 (Table 1).

Epidemiological surveillance of COVID-19 has represented a global challenge for health systems, requiring adaptive and efficient approaches to its monitoring. Among the systems implemented, sentinel surveillance and universal surveillance

Figure 1. Flow diagram according to the PRISMA-ScR statement for integrating COVID-19 into sentinel surveillance systems.



PRISMA-ScR: Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews.
Source: Prepared by the authors based on the results of the study.

Table 1. Characterization of the results.

Attribute	44 papers, 12 countries (100%)
Origin of the article by region of the world	Latin America and the Caribbean: 0 countries Europe and North America: 8 countries Asia and the Pacific: 3 countries Africa: 3 countries Arab States: 1 country
Year of publication	2021: 1 article 2022: 6 articles 2023: 10 articles
Type of reference	Systematic review: 1 article Cross-sectional studies: 16 articles Reports: 1 article

Source: Prepared by the authors of this study.

have been widely discussed in terms of their performance, sustainability and capacity to generate relevant information in diverse contexts. Based on the evidence available between 2020 and 2023, eight key characteristics have been evaluated: sustainability, geographic representativeness, coinfection monitoring, resource efficiency, early detection, variant detection, cost-effectiveness and sequencing capacity. The results are classified as positive, potentially positive, and inconclusive, with the amount of evidence supporting each finding also indicated (Figure 2).

Clinical features

The frequency of signs and symptoms constitutes a crucial element in developing a case definition within the framework of sentinel surveillance. In this context, the results of three studies analyzed the clinical characteristics of COVID-19 in different geographical settings. These findings highlight fever and cough as the most prevalent symptoms, although

Figure 2. Comparison of COVID-19 surveillance systems. Sentinel versus universal evidence-based surveillance 2020 to 2023.



Source: epidemiological surveillance studies from 2020 to 2023.

significant differences are observed according to the characteristics of the population and the setting evaluated (Table 2).

Additionally, the WHO, in its latest publication on the strategy for integrating COVID-19, reported sensitivity and specificity based on the case definitions used for influenza surveillance, yielding similar values for comparison (Table 3).

Timely detection and response

Studies conducted between 2022 and 2023 have demonstrated that sentinel surveillance enables the early identification of epidemic peaks, concurrent circulation of respiratory pathogens, and SARS-CoV-2 positivity rates. In addition, these have provided essential information for public health decision-mak-

Table 2. Comparison of clinical findings of COVID-19.

Location and year	Study design	Key features	Median prevalence of symptoms
United Kingdom, 2022	Systematic review (14 studies)	Addresses definitions ILI, ARI, SARI. China (69.7%), Europe (23.9%), and the United States (9.0%).	General symptoms: fever (73%, IQR = 58.3 to 78.7), cough (51.8%, IQR = 45 to 59.7), loss of taste or smell (45.1%, IQR = 28.9 to 54.0), hypoxemia (33%), expectoration (23.9%, IQR = 23.3 to 25.5).
			Adults: loss of taste/olfactory (30.5%, IQR = 15.7 to 45.2), hypoxemia (33%).
			Children: fever (58.3%, IQR = 56.6–59.9), cough (43%, IQR = 42 to 44), headache (34.3%, IQR = 18 to 50.7), nasal congestion (20%), muscle ache (19.6%, IQR = 11.8 to 27.3).
California, USA, 2022	Cross-sectional study	Community transmission monitoring (n = 1696)	Cough (55.6%), headache (48.6%), muscle pain (44.5%), sore throat (37.4%), and fever (35.3%).
Kenya, 2022	Cross-sectional study	Surveillance of SARS-CoV-2 and other pathogens (n = 177)	Rhinorrhea (68.4%), fatigue (54.1%), myalgia (53.7%), fever (52%), anosmia (24.9%), diarrhea (3.9%).

ILI: influenza-like illness. SARI: Severe Acute Respiratory Infection. ARI: acute respiratory infection. IQR: interquartile range.
Critical appraisal data from the included evidence sources are available at: https://doi.org/10.6084/m9.figshare.27273600.v.
Source: Prepared by the authors of this study.

Table 3. Summary of the performance characteristics of the case definitions.

	Influenza		COVID-19 (2021 evaluation)	
	Sensitivity	Specificity	Sensitivity	Specificity
ILI	45 to 55%	85 to 95%	20 to 55%	38 to 90%
ARI	94%	27%	60 to 96%	10 to 45%
SARI	45 to 70%	45 to 70%	33 to 62%	31 to 77%

ILI: influenza-like illness. SARI: severe acute respiratory infection. ARI: acute respiratory infection.
Source: *End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance.*

ing and the design of epidemiological control strategies (Table 4).

Geographical representativeness

Surveillance systems require samples to be representative of the general population, as demonstrated by a study conducted in Washington, USA, which analyzed the geographic extent of available sequencing data for COVID-19 cases using a hotspot map. Prior to the implementation of sentinel surveillance, only 3.3% of confirmed cases (10 653 of 323 121 total cases) had sequencing information available, which limited the representativeness of the geographic data. However, during the period when sentinel surveillance was implemented, this percentage increased to 12.1% (56 106 cases sampled). This allowed for greater coverage and uniformity across counties. These results highlight the significant contribution of sentinel surveillance to improving the representativeness and utility of infectious disease monitoring systems.

Efficient use of resources

In three studies from Spain, it was observed that in the autonomous community of La Rioja, a comparison between sentinel and universal surveillance systems for monitoring acute respiratory infections (ARI) reveals that, although general trends show consistency, the sentinel surveillance system presents variations. For example, in children under four years of age, sentinel surveillance reached higher incidence peaks (4958 cases per 100 000 population compared to 3691 in universal surveillance), while in week 2 of 2022, it reported 3153.4 cases per 100 000 population compared to 1773 in universal surveillance. These differences in incidence reflect the ability of sentinel surveillance to capture epidemiological patterns. This enables the optimization of resources by reducing the need to monitor the entire population. In Castilla y León, 62 000 people (2.6% of the total population) were monitored by 68 strategically distributed basic surveillance units. This approach enabled the efficient capture of epidemiological trends and reduced operating costs, ensuring the sustainability of the surveillance system.

Coinfection

Coinfection with SARS-CoV-2 and other respiratory pathogens, such as influenza A, influenza B, and respiratory syncytial virus, is a clinical/epidemiological problem in East Africa, as evidenced by studies in Uganda and Kenya. During the study period, a total of 22 cases of coinfections were detected by surveillance centers for influenza/severe acute respiratory infection type diseases: 2 cases with SARS-CoV-2/AH3, 9 cases with SARS-CoV-2/B.1.1.7 (also known as B. 1.1.7 or B. 1.1.7), and 11 cases with SARS-CoV-2/AH1pdm09. On the other hand, in Kenya, out of a total of 1271 individuals, the most common co-infectious pathogens were Streptococcus pneumoniae (n =

Table 4. Main findings from COVID-19 monitoring.

Location and year	Intervention or study population	Main findings
Chicago, USA, 2022	Patients who received SARS-CoV-2 testing in community settings.	Sentinel surveillance showed increases in R(t) weeks before hospital data recorded the same increase.
Portugal, 2021 to 2022	Of these (n = 324 872), 13 952 met criteria for sentinel specimen with positive diagnosis in 3607 specimens.	Through Nowcasting with an assessment date of February 27, 2021, sentinel case counts, now predicted, suggested that R(t) had increased beyond 1.0.
Castilla y León, España, 2021 to 2022	SARI sentinel surveillance system based on electronic health records	A high correlation was obtained between SARI cases or hospitalizations for respiratory infection and COVID-19 incidence ($\rho = 0.78$ and $\rho = 0.82$, respectively). SARI cases detected the epidemic peak of COVID-19 one week earlier. A weak correlation was observed between SARI and influenza cases ($\rho = -0.20$).
Cataluña, España, 2019 to 2020	PIDARIC primary care network n = 878 respiratory samples from patients with ILI and ARI symptoms.	Weekly estimates of COVID-19 incidence are consistent with the universal surveillance conducted in Castilla y León until the change in national strategy (week 12 of 2022). The pooled Pearson correlation coefficient before that week was 0.997 ($p < 0.001$) and 0.996 ($p < 0.001$) and 0.921 ($p < 0.001$) for the epidemic and non-epidemic periods, respectively.
Egipto, 2022	Integrated surveillance of acute respiratory infections	A higher positivity rate was observed among SARI patients compared to ILI patients (45.7% versus 22.4%, $p < 0.01$). The majority of SARI cases (95.3%) were caused by SARS-CoV-2, compared with 65.4% of ILI cases.
China, 2022 to 2023	(n = 18 160)	Analyzing data from different regions of China (southwest, central, north, and northeast) the rate of SARS-CoV-2 positives peaked in week 51 (72.5%, 72.3%, 41.2%, and 37.5%, respectively). Using sentinel surveillance with ILI case definitions is capable of detecting peaks in the positive rate.
Bangladesh, 2022 to 2023	Patients monitored during the fifth and sixth waves of COVID-19	The majority of patients meeting the COVID-19 suspect case definition (2141, 91%) were identified in the outpatient departments of all surveillance hospitals, and of these, 865 (40%) were confirmed to have COVID-19. In contrast, among all patients enrolled in the inpatient department, 57 (28%) were found to be positive for COVID-19.
California, USA, 2022	(n = 115 844)	Among those positive for SARS-CoV-2, 29% met the ILI clinical case definition and 25.4% met the case definition. A smaller proportion of non-COVID-19 coronavirus-positive persons met ILI (21.1%) or CLI (17.4%) criteria, and even fewer of those positive for rhinovirus/enterovirus met either definition (17.2% for ILI and 13.6% for CLI). However, specificity exceeded 80% for the ILI and CLI definitions for SARS-CoV-2, rhinovirus/enterovirus, or a non-COVID-19 coronavirus.
Israel, 2022 to 2023	Positive for SARS-CoV-2: 30 381 cases	When the national positivity rate was 2% or lower, sentinel surveillance was insufficient to detect SARS-CoV-2 activity.

SARI: Severe Acute Respiratory Infection. ILI: Influenza-Like Illness.. PIDARIC: Pla d'informació de les infeccions respiratòries agudes a Catalunya. CLI: COVID-19-like illness.
Source: Prepared by the authors of this study.

29) and Haemophilus influenzae (n = 19), which accounted for 2.3% and 1.5% of all SARS-CoV-2-positive samples, respectively.

Adaptability with genomic surveillance

The ability to rapidly detect new pathogens is a key indicator of the effectiveness of a surveillance system. For example, a study conducted in Belgium with 5695 respiratory samples found that 1558 samples tested positive for SARS-CoV-2, and 925 of these samples were successfully sequenced.

Initial genomic surveillance enabled the evaluation of the epidemic growth rate of SARS-CoV-2 variants by examining the growth slopes during the epidemic phase. In these, BA.1 (23.21) was the highest, followed by B.1.617.2 (Delta, 13.87), BA.5 (12.10) and BA.2 (10.91), while P.1 (1.84) and BA.4 (1.92) had much slower growth. Variants such as B.1.351 and BA.3 showed no definite epidemic growth (R^2 indeterminate), and P.1 had a poor regression fit ($R^2 = 0.90$). Although B.1.617.2 achieved 100% weekly detection, other variants had varied peak detection levels, such as BA.2 (98.5%), BA.1 (95.3%), and B.1.1.7 (85.1%), in contrast to BA.3 (0.14%) and B.1.351 (4.6%). The period between initial detection and epidemic growth varied between 2 and 8 weeks, depending on the variant. This highlights the importance of early surveillance to identify rapidly spreading variants.

In Israel, genome sequencing, performed on sentinel samples positive for SARS-CoV-2, provided additional support for this same sentinel surveillance. In Niger, out of a total of 51

SARS-CoV-2 positive samples identified through the sentinel surveillance system, 23 (45.1%) were eligible for sequencing. This analysis revealed the identification of two Omicron sublineages, notably BA.5 and BA.3, as well as 14 XBB.1/XBB.1.5 sublineages and one recombinant XBD variant. The XBB.1.5 sublineage is of considerable concern due to its rapid spread in the United States, underscoring the importance of identifying and characterizing it through genomic surveillance. The latter demonstrates the ability to detect specific sublineages and recombinant variants, allowing monitoring of their spread and behavior.

DISCUSSION

The review demonstrates that the integration of COVID-19 into sentinel surveillance systems has improved the ability to monitor respiratory diseases. It has also enabled the early detection of epidemic thresholds and the identification of coinfections [27,28]. In this line, it could be an efficient tool to optimize resources, especially in scenarios where health systems faced economic constraints during the COVID-19 pandemic. This was particularly relevant in some countries, where the redirection of resources allowed for improved surveillance of high-incidence respiratory diseases [29].

The implementation of multiplex PCR tests has enabled the more accurate identification of coinfections between SARS-CoV-2 and other respiratory pathogens. Similarly, they have been useful for monitoring the simultaneous circulation of different respiratory viruses [30,31].

One of the primary challenges is integrating genomic surveillance into sentinel surveillance. More than 50% of countries already perform genetic sequencing, which offers a cost-effective and sustainable opportunity to track SARS-CoV-2 variants and strengthen the response to future pandemics [32].

The economic and operational implications vary significantly between countries, depending on their health systems and level of development. In countries with advanced health systems, such as Israel and Portugal, the preexistence of technological infrastructure, specialized personnel, and integrated digital health information systems facilitated the simultaneous implementation of sentinel and genomic surveillance for COVID-19. These countries achieved high sensitivity in detecting variants and epidemiological changes, as evidenced by the significant correlations reported in Portugal between cases of severe acute respiratory infection and the incidence of COVID-19. The capacity for genomic sequencing in these settings enabled the accurate characterization of circulating viral diversity and the early detection of emerging variants. This differs from resource-limited countries such as Niger and Bangladesh, which face significant challenges, including inadequate diagnostic infrastructure, limited information systems infrastructure, and a shortage of skilled personnel. These countries had to adapt their strategies by selectively prioritizing sentinel sites, reducing geographic coverage but maintaining population representativeness. In Niger, for example, only 45.1% of SARS-CoV-2-positive samples were eligible for sequencing, which could result in an incomplete characterization of circulating viral diversity. Despite these limitations, they successfully implemented functional systems that provided valuable epidemiological information for local decision-making.

Heterogeneity in sentinel surveillance systems across countries constitutes a significant methodological limitation for this review. Differences in operational case definitions (influenza-like illness, acute respiratory infection and severe acute respiratory infection), sentinel site selection criteria, sampling protocols and diagnostic algorithms employed make direct comparability of results difficult. For example, while some countries, such as Spain, implemented systems with high geographical representativeness (68 basic surveillance units in Castilla y León), others had to concentrate resources in specific areas. Likewise, the variability in genomic sequencing capacity (from less than 50% in low-resource countries to nearly 80% in developed countries) generates asymmetries in the detection and characterization of variants. Future studies should develop standardized frameworks for evaluating surveillance systems that explicitly address these contextual differences, allowing more robust comparisons between diverse settings.

CONCLUSION

Finally, WHO's interim guidance on integrating SARS-CoV-2 and influenza surveillance underscores the need for flexible surveillance systems, with strong government support and use of existing health infrastructure. This is to ensure an effective response to future health threats [26].

Contributor roles JGS and DPM: Conceptualization, Data Curation, Paper Development and Design, Writing: original draft, Writing: review and editing. DSR, JAI, EFT and AKZ: Writing: original draft, Writing: review and editing.

Funding This project did not receive any external financing.

Acknowledgments We are grateful to the Postgraduate Coordination of the Universidad UTE for their guidance and constant support during the development of this research and to the Cochrane Center Ecuador for their guidance, advice and experience that have been indispensable for the development and completion of this project.

Competing interests The authors have no conflicts of interest.

Language of submission Spanish.

Peer review and provenance Unsolicited. With external review by three peer reviewers and the statistical editor of the journal, all in double-blind mode.

Registro del protocolo El protocolo de esta revisión fue registrado previamente en Open Science Framework con el número de registro osf.io/69a4g.

REFERENCES

1. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19: 141–154. https://doi.org/10.1038/s41579-020-00459-7

2. Fernández G, Marco Q, Suarez F, Fernando A, Amado J, Federico L, et al. Módulos de principios de epidemiología para el control de enfermedades (MOPECE). Módulo 1: Presentación y marco conceptual. Módulo Principios Epidemiol para el Control Enfermedades. 2017;Available: 101. https://iris.paho.org/handle/10665.2/55839
3. Organización Mundial de la Salud. Programa Mundial de Influenza: Orientaciones Provisionales Revisadas. Mantenimiento de la vigilancia de la gripe y seguimiento del SARS-CoV-2. Adaptación del Sistema Mundial de Vigilancia y Respuesta a la Gripe (SMVRG) y de los sistemas centinela durante. 2022. https://iris.who.int/handle/10665/340623
4. Organización Mundial de la Salud. In: Vigilancia de salud pública en relación con la COVID-19, orientaciones provisionales [Internet]. 2022. https://www.who.int/es/publications/i/item/who-2019-nCoV-surveillanceguidance-2022.2
5. PAHO/OMS. Informe final Consulta ad hoc de expertos en la región de las Américas: retos, brechas y próximos pasos en la vigilancia de COVID 19 y su integración en la vigilancia de influenza y otros virus respiratorios. OPS/OMS | Organización Panamericana de la Sa. https://www.paho.org/es/documentos/informe-final-consulta-ad-hoc-expertos-region-americas-retos-brechas-proximos-pasos
6. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8: 19–32. https://doi.org/10.1080/1364557032000119616
7. In: JBI Critical Appraisal Tools | JBI [Internet]. Nov 2024. https://jbi.global/critical-appraisal-tools
8. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169: 467–473. https://doi.org/10.7326/M18-0850
9. Lee B, Ashcroft T, Agyei-Manu E, Farfan de los Godos E, Leow A, Krishan P, et al. Clinical features of COVID-19 for integration of COVID-19 into influenza surveillance: A systematic review. J Glob Health. 2022;12: 05012. https://doi.org/10.7189/jogh.12.05012
10. Vega-Alonso T, Lozano-Alonso JE, Ordax-Díez A, on behalf of the VIGIRA Research Group. Comprehensive surveillance of acute respiratory infections during the COVID-19 pandemic: a methodological approach using sentinel networks, Castilla y León, Spain, January 2020 to May 2022. Euro Surveill. 2023;28: 1. https://doi.org/10.2807/1560-7917.ES.2023.28.21.2200638
11. Martínez Ochoa EM, Quiñones Rubio C, Ibáñez Pérez AC, Bea Berges L, Blasco Alberdi M, Latasa Zamalloa P. Comparación de la vigilancia centinela de infecciones respiratorias agudas frente a la vigilancia universal en La Rioja en la temporada 2021-2022. Rev Esp Salud Publica. 2023;97: e202310088–e202310088. https://www.sanidad.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_cdrom/VOL97/ORIGINALES/RS97C_202310088.pdf
12. Jané M, Martínez A, Ciruela P, Mosquera M, Martínez MJ, Basile L, et al. Surveillance of SARS-CoV-2 virus circulation using Acute Respiratory Infections sentinel system of Catalonia (PIDIRAC) during the 2019-2020 season: A retrospective observational study. PLoS One. 2022;17. https://doi.org/10.1371/journal.pone.0264949
13. Denayer S, Dufrasne FE, Monsieurs B, van Eycken R, Houben S, Seyler L, et al. Genomic monitoring of SARS-CoV-2 variants using sentinel SARI hospital surveillance. Influenza Resp Viruses. 2023;17. https://onlinelibrary.wiley.com/toc/17502659/17/10 https://doi.org/10.1111/irv.13202
14. Ruttoh VK, Symekher SL, Majanja JM, Opanda SM, Chitechi EW, Wadegu M, et al. Tracking severe acute respiratory syndrome coronavirus 2 transmission and co-infection with other acute respiratory pathogens using a sentinel surveillance system in Rift Valley, Kenya. Influenza Resp Viruses. 2023;17: e13227. https://onlinelibrary.wiley.com/toc/17502659/17/11 https://doi.org/10.1111/irv.13227
15. Zeng X, Xie Y, Yang X, Peng Z, Tang J, Yang L, et al. SARS-CoV-2 Surveillance Through China Influenza Surveillance Information System - China, December 1, 2022 to February 12, 2023. China CDC Wkly. 2023;5: 152–158. https://doi.org/10.46234/ccdcw2023.027
16. Richardson R, Jorgensen E, Arevalo P, Holden TM, Gostic KM, Pacilli M, et al. Tracking changes in SARS-CoV-2 transmission with a novel outpatient sentinel surveillance system in Chicago, USA. Nat Commun. 2022;13: 5547. https://doi.org/10.1038/s41467-022-33317-6
17. Cooksey GLS, Morales C, Linde L, Schildhauer S, Guevara H, Chan E, et al. Severe Acute Respiratory Syndrome Coronavirus 2 and Respiratory Virus Sentinel Surveillance, California, USA, May 10, 2020–June 12, 2021. Emerg Infect Dis. 2022;28: 9–20. https://doi.org/10.3201/eid2801.211682
18. Oltean HN, Allen KJ, Frisbie L, Lunn SM, Torres LM, Manahan L, et al. Sentinel Surveillance System Implementation and Evaluation for SARS-CoV-2 Genomic Data, Washington, USA, 2020–2021. Emerg Infect Dis. 2023;29: 242–251. https://doi.org/10.3201/eid2902.221482
19. Torres AR, Gómez V, Kislaya I, Rodrigues AP, Fernandes Tavares M, Pereira AC, et al. Monitoring COVID-19 and Influenza: The Added Value of a Severe Acute Respiratory Infection Surveillance System in Portugal. Can J Infect Dis Med Microbiol. 2023;2023. https://doi.org/10.1155/2023/6590011
20. Fahim M, Abu ElSood H, AbdElGawad B, Deghedy O, Naguib A, Roshdy WH, et al. Adapting an integrated acute respiratory infections sentinel surveillance to the COVID-19 pandemic requirements, Egypt, 2020–2022. Public Health in Practice. 2023;5: 100358. https://doi.org/10.1016/j.puhip.2023.100358
21. BrombergM, Keinan-BokerL, Gur-Arie L, Sefty H, MandelboimM, Dichtiar R, et al. Monitoring SARS-CoV-2 Activity with Sentinel Surveillance: Lessons Learned from the First Wave in Israel. IMAJ The Israel Medicine Association Journal. 2022;24. https://www.ima.org.il/MedicineIMAJ/viewarticle.aspx?year=2022&month=04&page=215

22. Glatman-Freedman A, Gur-Arie L, Sefty H, Kaufman Z, Bromberg M, Dichtiar R, et al. The impact of SARS-CoV-2 on respiratory syndromic and sentinel surveillance in Israel, 2020: A new perspective on established systems. Euro Surveill. 2022;27: 2100457. https://doi.org/10.2807/1560-7917.ES.2022.27.16.2100457/CITE/REFWORKS
23. Kayiwa JT, Nassuna C, Mulei S, Kiggundu G, Nakaseegu J, Nabbuto M, et al. Integration of SARS-CoV-2 testing and genomic sequencing into influenza sentinel surveillance in Uganda, January to December 2022. Microbiol Spectr. 2023. https://doi.org/10.1128/SPECTRUM.01328-23/ASSET/470DDD52-DF82-42FA-9069-FCA8DCF15BE7/ASSETS/IMAGES/LARGE/SPECTRUM.01328-23.F004.JPG
24. Lagare A, Faye M, Issa M, Hamidou O, Bienvenu B, Mohamed A, et al. First identification of the SARS-COV-2/XBB.1.5 sublineage among indigenous COVID-19 cases through the influenza sentinel surveillance system in Niger. Heliyon. 2023;9. https://doi.org/10.1016/j.heliyon.2023.e20916
25. Das P, Akhtar Z, Mah-E-Muneer S, Islam MA, Rahman MZ, Rahman M, et al. Establishing a sentinel surveillance system for the novel COVID-19 in a resource-limited country: methods, system attributes and early findings. BMJ Open. 2021;11. https://doi.org/10.1136/bmjopen-2021-055169
26. In: Compendium of country approaches End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance [Internet]. 2023. http://apps.who.int/bookorders
27. Organización Panamericana de la Salud. In: Guía operativa para la vigilancia centinela de la Infección Respiratoria Aguda Grave (IRAG); 2014 - OPS/OMS | Organización Panamericana de la Salud [Internet]. 2014. https://www.paho.org/es/node/52153
28. Sierra Moros MJ, Martínez Sánchez EV, Monge Corella S, García San Miguel L, Suárez Rodríguez B, Simón Soria F. Lecciones de la vigilancia de la COVID-19. Necesidad urgente de una nueva vigilancia en salud pública. Informe SESPAS 2022. Gac Sanit. 2022;36: S68–S75. https://doi.org/10.1016/j.gaceta.2022.03.001
29. PAHO/OMS. In: Informe COVID-19: La prolongación de la crisis sanitaria y su impacto en la salud, la economía y el desarrollo social [Internet]. 2022. https://www.paho.org/es/documentos/prolongacion-crisis-sanitaria-su-impacto-salud-economia-desarrollo-social
30. Sanz-Muñoz I, Castrodeza Sanz J, María Eiros J. Vigilancia de la COVID-19 tras la pandemia. ¿Cómo lo hacemos? Medicina Clínica. 2022;159: 396–400. https://doi.org/10.1016/j.medcli.2022.05.010
31. Swets MC, Russell CD, Harrison EM, Docherty AB, Lone N, Girvan M, et al. SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses. Lancet. 2022;399: 1463–1464. https://doi.org/10.1016/S0140-6736(22)00383-X
32. Chen Z, Azman AS, Chen X, Zou J, Tian Y, Sun R, et al. Global landscape of SARS-CoV-2 genomic surveillance and data sharing. Nat Genet. 2022;54: 499–507. https://doi.org/10.1038/s41588-022-01033-y

Evidencia disponible de integración de COVID-19 a sistemas de vigilancia centinela: revisión de alcance

RESUMEN

INTRODUCCIÓN La pandemia de COVID-19 evidenció las debilidades de los sistemas de vigilancia epidemiológica y resaltó la necesidad de integrar nuevos virus respiratorios en los sistemas de vigilancia centinela. Sin embargo, la evidencia actual sobre su eficacia sigue siendo limitada.

OBJETIVO Este proyecto lleva a cabo una revisión del alcance para describir la evidencia disponible sobre el impacto de la integración del COVID-19 a los sistemas de vigilancia centinela.

MÉTODOS Los estudios incluidos abordaron la vigilancia centinela en el contexto de la pandemia tras la declaración de la Organización Mundial de la Salud (OMS). Se realizó una búsqueda sistemática en bases de datos como MEDLINE/PubMed, LILACS, Epistemonikos y Dimensions. Se utilizaron estudios observacionales y revisiones sistemáticas. La recopilación y el análisis de datos se organizaron en categorías como características clínicas, detección oportuna, representatividad geográfica, coinfección y adaptabilidad con la vigilancia genómica. Se identificaron 17 estudios que informaron sobre el impacto de la integración de COVID-19 y un informe preliminar de la OMS.

RESULTADOS Los resultados mostraron entre los síntomas más prevalentes en la población general: fiebre (73%), tos (51,8%), pérdida de gusto u olfato (45,1%), hipoxemia (33%), expectoración (23,9%). Se obtuvo una alta correlación entre los casos de infección respiratoria aguda grave (SARI) u hospitalizaciones por infección respiratoria y la incidencia de COVID-19 ($\rho = 0,78$ y $\rho = 0,82$ respectivamente).

CONCLUSIONES La integración de COVID-19 al sistema de vigilancia centinela podría mejorar la capacidad de detección, respuesta y seguimiento. Asimismo. la utilización de definiciones de caso conduce a un uso más eficiente de pruebas de laboratorio que asegura la sostenibilidad del sistema de vigilancia